Clinico-pathological characteristics | Number of patients (%) with CETCs | Median of CETC counts | P-value | Median (%) of AR positive CETCs | P-value | Median (%) of ER positive CETCs | P-value |
---|---|---|---|---|---|---|---|
Age (years) | |||||||
āĀ ā¤ā50 | 26 (39) | 85 | 0.001 | 90 | 0.98 | 50 | 0.91 |
āĀ >ā50 | 40 (61) | 30 | 89 | 50 | |||
Tumor size | |||||||
Ā T1 | 29 (44) | 35 | 0.34 | 83 | 0.42 | 50 | 0.86 |
Ā T2 | 34 (51) | 35 | 80 | 50 | |||
Ā T3 | 2 (3) | 120 | 73 | 62 | |||
Ā n.a | 1 (2) | Ā | Ā | Ā | |||
Lymph node metastasis | |||||||
Ā Positive | 25 (38) | 40 | 0.63 | 86 | 0.04 | 50 | 0.63 |
Ā Negative | 40 (61) | 35 | 93 | 50 | |||
Ā n.a | 1 (1) | Ā | Ā | Ā | |||
Distant metastasis | |||||||
Ā Positive | 7 (11) | 85 | 0.11 | 88 | 0.99 | 49 | 0.97 |
Ā Negative | 58 (88) | 35 | 89 | 50 | |||
Ā n.a | 1 (1) | Ā | Ā | Ā | |||
Stage | |||||||
Ā I/II | 49 (74) | 30 | 0.009 | 90 | 0.93 | 51 | 0.16 |
Ā III/IV | 17 (26) | 95 | 89 | 62 | |||
HER2 status | |||||||
Ā Positive | 21 (32) | 35 | 0.58 | 89 | 0.93 | 56 | 0.37 |
Ā Negative | 45 (68) | 35 | 90 | 52 | |||
ER/PR status | |||||||
Ā Positive | 51 (77) | 35 | 0.97 | 87 | 0.74 | 52 | 0.82 |
Ā Negative | 15 (23) | 35 | 88 | 46 | |||
Radiation | |||||||
Ā Yes | 24 (36) | 40 | 0.93 | 92 | 0.19 | 48 | 0.27 |
Ā No | 34 (52) | 40 | 88 | 52 | |||
Ā n.a | 8 (12) | Ā | Ā | Ā | |||
Hormone receptor status | |||||||
Ā TNBC | 10 (16) | 55 | 0.31 | 91 | 0.02 | 56 | 0.55 |
Ā ER/PR pos. | 51 (84) | 35 | 83 | 46 | |||
Hormone therapy | |||||||
Ā Yes | 33 (50) | 35 | 0.77 | 89 | 0.57 | 47 | 0.07 |
Ā No | 32 (49) | 35 | 91 | 60 | |||
Ā n.a | 1 (1) | Ā | Ā | Ā | |||
Chemotherapy | |||||||
Yes | 30 (45) | 50 | 0.51 | 90 | 0.47 | 52 | 0.96 |
No | 36 (55) | 35 | 88 | 48 | |||
Tamoxifen therapy | |||||||
Ā Yes | 22 (33) | 35 | 0.64 | 90 | 0.75 | 45 | 0.042 |
Ā No | 43 (66) | 35 | 91 | 58 | |||
Ā n.a | 1 (1) | Ā | Ā | Ā | |||
Aromatase inhibitor | |||||||
Ā Yes | 19 (29) | 50 | 0.29 | 85 | 0.22 | 50 | 0.35 |
Ā No | 46 (70) | 35 | 91 | 39 | |||
Ā n.a | 1 (1) | Ā | Ā | Ā |